Is Teneligliptin Safe in Patients with Diabetes Mellitus Mainly with Reference to QT Prolongation.

ABSTRACT

Diabetes mellitus (DM) is a chronic disease associated with polyurea, polydipsia, and polyphagia. It is associated severe complication if not controlled properly. The probability of developing cardiac arrythmia is more in patients with diabetes compared to general population. Previously, studies which used a maximum dose of 40 mg of Teneligliptin didn’t show any QT prolongation. There are hardly any studies which was done to prove the cardio safety of Teneligliptin. Therefore, we wanted to evaluate the prevalence of QT prolongation with teneligliptin in diabetic patients. MethodsWe analysed all patients who were treated with teneligliptin. We analysed ECG of all patients before and after therapy with teneligliptin. Our main aim was to compare the QT interval in ECG before and at the end of 3 months. We also analysed their HbA1c, fasting plasma glucose (FPG), and postprandial plasma glucose (PPG) before and after therapy. ResultsThe mean age of these patients was 55.5 ± 10.6 years. They were on treatment for diabetes with a mean duration of diabetes of 7.9 ± 5.7 years. All patients responded well to the treatment with a reduction in HbA1c, FBS and PPBS, all of those being statistically significant. When we analysed the QT interval of all patients before and after three months of therapy, there was no significant increase in the mean QTc interval at the end of 3 months. All of them tolerated the drug without any serious adverse effects. ConclusionsTeneligliptin in dose of 20 mg didn’t prolong QTc interval; meanwhile, it was found to be very effective in reducing the HbA1c, fasting plasma glucose, and post prandial plasma glucose at the end of 3 months.